Literature DB >> 28709759

Total Hip Arthroplasty Outcomes: An 18-Year Experience in a Single Center: Is Systemic Lupus Erythematosus a Potential Risk Factor for Adverse Outcomes?

Javier Merayo-Chalico1, Marco Gónzalez-Contreras1, Rigoberto Ortíz-Hernández1, Jorge Alcocer-Varela1, David Marcial2, Diana Gómez-Martín1.   

Abstract

BACKGROUND: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications. About 30% of these patients become candidates for surgical treatment. The aim of this study was to evaluate postoperative outcomes after total hip arthroplasty (THA) in SLE patients.
METHODS: We performed a retrospective cohort study at a tertiary care center in Mexico City between 1995 and 2013. All patients with SLE who underwent THA during that period were included (n = 58). They were compared with 2 control groups, one from another inflammatory arthropathy (rheumatoid arthritis, n = 58) and other noninflammatory (osteoarthritis, n = 58), matched by gender and date of surgery. The primary outcome was the frequency of postoperative complications during follow-up.
RESULTS: We included 174 patients who underwent THA during the study period. Patients with SLE were younger (P < .0001), had a longer hospitalization stay (P = .001), and required more transfusions (P = .004). Global complications in THA in patients with SLE were more prevalent than rheumatoid arthritis (36.2% vs 15.5%, P = .029) and osteoarthritis (36.2% vs 5.1%, P < .0001) patients. After multivariate analysis, risk factors for THA complications were: SLE (hazard ratio 2.8, 95% confidence interval 1.2-6.8; P = .018) and low postoperative hemoglobin (hazard ratio 0.77, 95% confidence interval 0.73-0.83; P < .0001). Long-term complications after THA were similar among groups.
CONCLUSION: This is the largest single-center study regarding clinical outcomes after THA in SLE patients. Our data suggest that SLE is an independent risk factor for adverse postoperative outcomes, mainly immediate complications, but the long-term outcome is good enough to offer surgical treatment that will improve quality of life.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  osteonecrosis; postoperative complications; systemic lupus erythematosus; total hip arthroplasty; transfusions

Mesh:

Year:  2017        PMID: 28709759     DOI: 10.1016/j.arth.2017.06.021

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  5 in total

Review 1.  Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression.

Authors:  Joshua F Baker; Michael D George
Journal:  Curr Rheumatol Rep       Date:  2019-03-08       Impact factor: 4.592

2.  Is osteonecrosis due to systemic lupus erythematosus associated with increased risk of complications following total hip arthroplasty?

Authors:  Dennis Q Chen; Jourdan M Cancienne; Brian C Werner; Quanjun Cui
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

3.  Systemic Lupus Erythematosus is a Risk Factor for Complications in Total Joint Arthroplasty.

Authors:  J Joseph Gholson; Brandon G Wilkinson; Timothy S Brown; Yubo Gao; S Blake Dowdle; John J Callaghan
Journal:  Iowa Orthop J       Date:  2018

4.  A systematic review and meta-analysis comparing complications following total hip arthroplasty for systemic lupus erythematosus versus for non-systemic lupus erythematosus.

Authors:  Yiwei Huang; Danni Guan; Yijin Li; Jiahao Li; Yirong Zeng
Journal:  J Orthop Surg Res       Date:  2022-04-12       Impact factor: 2.359

5.  The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study.

Authors:  Chien-Hao Chen; Tien-Hsing Chen; Yu-Sheng Lin; Dave W Chen; Chi-Chin Sun; Liang-Tseng Kuo; Shih-Chieh Shao
Journal:  Arthritis Res Ther       Date:  2020-09-14       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.